Open AccessEpidemiology, Evaluation and Management of Anti-Phospholipid Syndrome
Author(s) -
Mohammed Salah Hussein,
Ali Alsharif,
Yazeed Alhofair,
Abdulrahman Mohammed S. Alhuraysi,
Mohamed Fouad Alabsi,
Ibrahim A. Kattan,
Khalid Anwar A. Abo Alela,
Mohammed Fawzi Mujallid,
Ferass Zeyad Timraz,
Zahra Ahmed Alhababi,
Tayil Mutiq Alrashidi,
Hazem Khairan Althobaiti,
Malak Abdulrahman Rajeh,
Ahmed Sadaka Kadi,
Amal Ahmad Mobarki
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i60b34759
Subject(s) - antiphospholipid syndrome , medicine , warfarin , etiology , thrombosis , aspirin , vitamin k antagonist , epidemiology , immunology , intensive care medicine , atrial fibrillation
Antiphospholipid syndrome is defined as the presence of antiphospholipid antibodies in the setting of thrombosis and/or pregnancy loss (APLS).Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory condition that affects individuals and their families in a negative and often fatal way. There are the two types of APS: Primary APS, which develops on its own, and secondary APS, which is linked to another autoimmune disorder, most often systemic lupus erythematosus (SLE). The HLA-DR7, DR4, DRw53, DQw7, and C4 null alleles have all been linked to APLS. APS is frequently misdiagnosed due to clinical diversity and a lack of diagnostic test consistency. The classification criteria were created to categorise APS patients for research reasons, but they can also be used by professionals to establish diagnoses. Unprovoked thrombosis is currently treated with long-term warfarin or another vitamin K antagonist drug. To avoid obstetric complications, low-dose aspirin and prophylactic heparin, primarily low-molecular-weight heparin, are utilised.In this article we’ll be looking at Anti-phospholipid Syndrome, it’s etiology, epidemiology, evaluation and management.